Epsilogen Acquires TigaTx to Form Pan-Isotype Cancer Antibody Leader

Epsilogen has acquired TigaTx, creating the world's leading pan-isotype cancer antibody company. The combined company will have expertise in IgE, IgA, and IgG, allowing for the selection of the most relevant isotype for a given cancer and the creation of hybrid antibodies that activate multiple immune compartments. The acquisition aims to pioneer new antibody therapeutics in oncology.

London & Boston, Apr 7, 2025—Epsilogen, a global leader in the development of immunoglobulin E (IgE) antibody therapeutics, has completed the acquisition of TigaTx, Inc., a biotechnology company specializing in engineered immunoglobulin A (IgA) antibodies. This strategic move aims to create the world's leading pan-isotype cancer antibody company, combining Epsilogen's expertise in IgE, IgA, and IgG isotypes.

The acquisition, which makes US-based TigaTx a wholly owned subsidiary of Epsilogen, was announced by Epsilogen CEO Tim Wilson. He commented, "We are excited to create the world’s leading pan-isotype antibody company with the goal of bringing improved therapeutics to cancer patients. Combining the capabilities of Epsilogen with those of TigaTx gives us the ability to choose the most relevant isotype for a given cancer, whether a cold tumor environment we want to drive multiple immune effector cells into or leverage neutrophils."

The transaction also facilitates the combination of different isotype functions into a single antibody molecule, a capability that could activate multiple compartments of the immune system and possess improved PK/PD profiles. This is especially powerful given the importance of the epitope in determining the clinical performance of antibodies.

TigaTx's pipeline includes EPS 401 (formerly TIGA-001), an anti-EGFR IgA antibody scheduled to enter the clinic in 2026, and MOv18 IgE, currently in a Phase Ib trial for treatment of platinum-resistant ovarian cancer. Epsilogen's earlier stage pipeline features several other IgE antibody candidates targeting various tumor antigens.

Dr. Sonia Gulati, a Principal at Global BioAccess Fund and newly appointed to Epsilogen's Board of Directors, expressed her enthusiasm about the merger. "We are thrilled about the merger with Epsilogen and believe deeply in the potential of IgA and IgE-based therapies to transform cancer treatment. Together, we are advancing a new frontier in immunotherapy to bring innovative solutions to patients in need."

Pete Finan, Epsilogen’s Non-Executive Chairman and a General Partner at Epidarex Capital, added, "Nature has evolved five different antibody isotypes to perform specific biologic functions. Following the acquisition, Epsilogen is in a unique position with in-house deep expertise in three of these, IgE, IgA and IgG. We very much look forward to the company turning this potential into innovative new medicines for cancer patients."

The acquisition aligns with Epsilogen's mission to pioneer new antibody therapeutics in oncology by leveraging the distinct and potent immunological effector functions of IgE and IgA antibodies. This strategic move positions Epsilogen at the forefront of cancer immunotherapy, offering a promising approach to treating various cancer types.